Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Filippo de Marinis"'
Publikováno v:
The Thoracic and Cardiovascular Surgeon. 70:273-276
This case series aimed to analyze the outcomes of patients referred for salvage pulmonary resections after treatment with chemotherapy and immunotherapy for previously metastatic or unresectable tumors.From October 2016, after multidisciplinary board
Autor:
Paolo Tarantino, Ilaria Attili, Filippo de Marinis, Giuseppe Curigliano, Valeria Stati, Antonio Passaro
Publikováno v:
Lung Cancer. 154:151-160
The adoption of Immune checkpoint inhibitors (ICIs) allowed the achievement of impressive long-term survival results in non-small cell lung cancer (NSCLC), but most patients develop resistance to ICI treatment over time. Resistance to ICIs is mediate
Autor:
Jillian Wilhelmina Paulina Bracht, Valentina Guarneri, Ana Giménez-Capitán, Carles Codony-Servat, Filippo de Marinis, Giulia Pasello, Miguel Angel Molina-Vila, Rafael Rosell, Pierfranco Conte, Antonio Passaro, Imane Chaib, Matteo Fassan, Alessandro Dal Maso, Jordi Codony-Servat, Erika Aldeguer, Niki Karachaliou, Laura Bonanno, Jordi Berenguer, Ilaria Attili
Publikováno v:
Translational Lung Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
Background: The role of MET alterations in non-small cell lung cancer (NSCLC) is increasing and several targeted agents are under evaluation. MET exon 14 skipping mutations and MET amplifications are associated with potential sensitivity to MET inhib
Autor:
Lorenzo Spaggiari, Marina Chiara Garassino, Filippo de Marinis, Roberto Ferrara, Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Gaia Piperno, Giuseppe Lo Russo, Giulia Corrao, Roberto Orecchia, Simone Giovanni Gugliandolo
Publikováno v:
Lung Cancer. 142:70-79
Presence of liver metastases correlates with worse survival and response to any treatments. This may be due to the microenvironment of liver which leads tumor to escape from Immune System. Stereotactic Body Radiation Therapy may help to sensitize Imm
Autor:
Filippo de Marinis, Helano C. Freitas, Yi-Long Wu, David Vicente, Gee-Chen Chang, Mariano Provencio, Nicolaas A. Bakker, J. Rigas, Sang We Kim, Qing Zhou, Liyan Jiang, Parneet Cheema, Gilberto de Castro, Claudio Martin, Giulio Metro, Byoung Chul Cho, Miguel F. Miranda, Johan Vansteenkiste, Yuh Min Chen
Publikováno v:
Future Oncology. 15:3003-3014
Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. We report real-world effectiveness and safety data. Patients & methods: EGFR T790M positive advanced non-small-cell lung cancer adults, who received ≥1 prior
Autor:
Jun Zhao, B J Srinivasa, Hai-Yan Tu, Konstantin Laktionov, Filippo de Marinis, Tejaswini Jalikop, Jifeng Feng, Eng Huat Tan, Victor C. S. Lee, Cheng-Ta Yang, Dariusz M. Kowalski, Maya Gottfried, Yi-Long Wu, Artem Poltoratskiy, Dennis Chin-Lun Huang, Agnieszka Cseh, Keunchil Park, L. Clementi, Antonio Passaro
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundAfatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). Here, we report findings from a combined analysis of three phase IIIb studies of
Autor:
Ilaria Attili, Filippo de Marinis, Emilio Bria, Domenico Galetta, Alain Gelibter, Maria Lucia Reale, Diana Giannarelli, Valeria Stati, Pamela Pizzutilo, Alessio Stefani, Silvia Novello, Antonio Passaro, Simona Carnio, Emanuele Vita
Publikováno v:
Cancers, Vol 13, Iss 2935, p 2935 (2021)
Cancers
Volume 13
Issue 12
Cancers
Volume 13
Issue 12
Background: Pembrolizumab is approved in monotherapy for the first-line (1L) of advanced or metastatic NSCLC patients with high PD-L1 (≥50%). Despite a proportion of patients achieve long-term survival, about one-third of patients experience detrim
Autor:
Paolo Bidoli, Daniele Turci, Hector Soto Parra, Domenico Galetta, Fabiana Vitiello, Teresa Gamucci, Paola Antonelli, Filippo de Marinis, Giuseppe Lo Russo, Angelo Delmonte, Enrico Cortesi, Francesco Grossi, Luana Calabrò, Andrea Ardizzoni, Alessandro Morabito, Diana Giannarelli, Antonio Chella, Federico Cappuzzo, Lucio Crinò, Marcello Tiseo
Publikováno v:
The Oncologist. 24:e1165-e1171
Background Nivolumab has shown a survival benefit compared with docetaxel as second-line treatment for patients with previously treated advanced squamous non-small cell lung cancer (NSCLC) in a randomized phase III trial. The experiences of patients
Autor:
Carlo Putzu, Filippo de Marinis, Laura Bonanno, Sara Pilotto, Antonio Passaro, Lorenza Landi, Carlo Genova, Danilo Rocco, Rita Chiari, Luca Toschi, Chiara Bennati, Arsela Prelaj, Diego Cortinovis, Andrea Camerini, Marcello Tiseo, Claudia Proto, Federico Cappuzzo, Claudio Sini, Alessandro Tuzi, Giulio Cerea, Gianluca Spitaleri
Publikováno v:
Clinical Lung Cancer. 20:e186-e194
Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined predictive and druggable mutations that greatly modified patient prognoses. The most frequent driver mutations detected in NSCLC are epidermal growth factor recept
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75